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Summary: A chromogenic assay for the determination of factor XII using the chromogenic substrate Chromozym
PK® was evaluated. The assay was linear in the range 10 U/l to more than 200 U/l. Using the assay, the normal range
of factor XII (50 healthy volunteers at random) was 136 U/l ± 27 U/l. Kallikrein-inhibiting concentrations of aproti-
nin did not influence factor XII. Comparison of the chromogenic with the clotting assay resulted in a correlation
coefficient of r = 0.831 (p-value < 0.001). In patients with deep vein thrombosis, factor XII level was found to be
reduced to about 60% of normal activity.
Ein photometrisches Verfahren zur Faktor ΧΠ-Bestimmung mit dem chromogenen Substrat Chromozym PK®
Zusammenfassung: Es wird ber ein photometrisches Verfahren zur Faktor XII-Bestimmung mit dem chromogenen
Substrat Chromozym PK® berichtet. Linearit t ist bis zu mehr als 200 U/l gew hrleistet. Bei 50 gesunden Probanden
wurde der Normalbereich zu 136 U/l ± 27 U/l ermittelt. Ein Zusatz von Aprotinin, der zu einer vollst ndigen Hem-
mung von Kallikrein fuhrt, verursachte keine Hemmung der Faktor XII-Aktivit t. Der methodische Vergleich mit dem
Einphasentest nach Ratnoff& Colopy ((1955) J. Clin. Invest. 34,602-614) ergab einen Korrelationskoeffizienten
von r ^ 0.831 (p < 0.001). Patienten mit einer tiefen Venenthrombose wiesen eine um 40% erniedrigte Faktor XII-
Aktivit t auf. ·
Introduction tor is known to be the major inhibitor of kallikrein (3).
_ Λ V¥T , , u - ... .. ,.,.. . Consequently, factorXII determination can be carriedFactor XII can be measured by exploiting its ability to * ΛΛ.*· r i n-, -. t „., . f ' , ,,., - . ^ , + , out with the addition of a new pre-kallikrein source togenerate kallikrein from prekallikrein. Cochrane et al. u . r .,, l r . . ^_ ι ^ · i_-1.1 -r· Λ the sample, after the kallikrein of the sample is inhibited,used benzoyl-L-arginine ethyl ester in an highly purified F ' ·* . * @
" * ' Λι * - *u - + A ̂  n-t- - A\U7-+U The use of the chromogenic substrate Chromozym PK^system to detenrune the generated kalbkrein(l). With . fe J .
':' , A \ r i . · u x ^ r ι for factor XII determination and its diagnostic value mthe development of a chromogenic substrate for plasma - , 4. .. · , . 4. A 6 , . ... . ,, «^ . ,™ nrs® I - -1" ι ι ι. ι tiiTombotic diseases has been investigated in this study.kaHikrem (Chromozym PK , benzoyl-prolykphenyl- 6 J
alanyl^arginine^-nitroanilide), this assay can be modified
for measurement in plasma. Kluft has demonstrated that Methods aqd Materials
factor XII itself does not split the chromogenic sub-
strate (2). On the other hand, it is necessary to rule out - mpe*
t .~ *,.^. r u.t_ - t. χ * u i · A To obtain the normal range, the assay for factor XII was carriedthe unspecific splitting of the substrate by plasmin and put on 50 healthy volunteers selected at random> who showed
trypsin. Cochrane et al. did not observe any influence of normal levels for partial thromboplastin time, thrombin time,
2.5 g/1 of e-aminocaproic acid on the activation of factor fibrinogen, and antithrombin III.
XII (1). It is well established that after activation of ^
plasma with negatively charged particles, kallikrein ι ̂  Reported in part at the 7th World Congress on Thrombosis
becomes inactivated within minutes. Cl esterase inhibi- and H emostasis in London, July 1979.
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Furthermore, the assay was carried out daily during one week on
10 healthy volunteers (aged from 36 to 54 years) and on
10 patients with deep vein thrombosis (4 male, 6 female, aged
from 32 to 69 years) receiving treatment with a therapeutic
dose of heparin (600 I. U./d · kg body weight).
Citrated blood was taken (1 vol. sodium citrate and 9 parts of
venous blood) and immediately centrifuged at 3000 U/min for
10 minutes at 4 °C. Samples were then stored at - 40 °C. Pool
plasma was obtained from at least 20 healthy donors, immedi-
ately frozen and thawed at 37 °C just before use.
Procedures
Clotting factor XII assay was performed according to Ratnoff
& Colopy (4). Standard procedures were used for the anti-
thrombin III assay with the chromogenic substrate Chromo-
zym TH® (Boehringer Mannheim, FRG) (5), partial thrombo-
plastin time (6), thrombin time (7), and fibrinogen (8).
Materials
Factor XH-deficient plasma (of congenital deficiency) was
obtained from Merz & Dade (Bern, Switzerland), aprotinin
(Trasylol®) from Bayer Leverkusen, Cephotest® from Nyegaard
(Oslo, Norway), and the chromogenic substrates from Boehrin-
ger Mannheim (FRG). Prof. Opferkuch, Bochum, and Prof.
Loos, Mainz, kindly supplied preparations of complement
subcomponents: Cl esterase (specific activity 3800 U/mg
protein with N-acetyl-Z-tyrosine ethyl ester as the substrate)
and Clq subcomponent (specific activity 3.5 X 10IS effective




In figure 1 the inactivation ofkallikrein is shown after
activation of normal human plasma with Cephotest®
using the procedure described by Stormoken et al. (20).
Furthermore, it is obvious that the kallikrein activating
activity remains unchanged up to 120 minutes after
activation with kaolin.
Activation of factor XII
Because the activator of factor XII has to be removed,
kaolin was added as an activator. 2.5 g/1 of e-amino-
caproic acid was added to preclude an activation of the
fibrinolytic system.
After incubation of plasma with 5 g/1 of kaolin in a ratio
of 1:1 at 37 °C for 3 minutes, kaolin was removed by
centrifugation for 10 minutes at 3000 # at room tem-
perature. The sample was then allowed to stand at 37 °C
for one hour to inactivate the kallikrein.
Elimination of XII (fragment) activity
It is known that the XHf activity can be inhibited by
addition of 0.3 mol/1 of sodium chloride (12,13). The
influence of increasing addition of sodium chloride in
the photometric assay can be taken from figure 2. After
addition of 0.3 mql/1 of sodium chloride to the assay
solution, the remaining activity can be attributed to the
factor XII a molecule.
Photometric assay
The buffer used consisted of Tris (final concentration
0.03 mol/1), sodium chloride (final concentration
0.3 mol/1), and aprotinin (final concentration
2.5 nmol/1), adjusted to pH 8.0 with HCl (1 mol/1). In
further experiments 50 /il pool plasma was found to be
sufficient as a prekallikrein source in the assay.
The reaction mixture can be summarized as follows:
300 μΐ buffer
50 μΐ pool plasma (as a prekallikrein source)
50 μΐ activated plasma (sample)
allow to stand for 60 seconds, then start with 100 μΐ
Chromozym PK@ (final concentration 250 μπίοΐ/ΐ).
The activity can be calculated from the increasing ab-
sorbance at 405 nrii. An assay performed on factor XH-
deficient plasma revealed no detectable activity. The
principle of the assay is summarized in table 1.
Tab. 1. Principle of the chromogenic assay:
kaolin (3 min at 37 C)
factor XII ^ "· ^activated factor XII
incubation (l h at 37 °C)
kallikrein (sample) " ^= ^ kallikrein (inactive)
XII a
prekallikrein (new source)" kallikrein
kallikrein




t ( m i n )
80 " 120
Fig. 1. Kinetics of inactivation of kallikrein (·) in plasma while
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Fig. 2. Elimination of factor XIIf (fragment) activity: addition
of sodium chloride to the photometric reaction mixture.
• (standard conditions).
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Influence of storage on factor XII and prekallikrein
Storage of normal human plasma at 4 °C resulted in the
well-known initial decrease of prekallikrein. On the
other hand, factor XII levels remained constant within
the first 24 hours, followed by a slight decrease (fig. 3).
Linearity of the assay
A linear slope function can be obtained up to 200 U/l
(% 4).
Within-run precision
For the determination of the within-run precision the
chromogenic as well as the clotting assay were per-
formed 20 times in pool plasma. For the chromogenic
assay, χ = 139 ± 4.1 U/l (variation coefficient 2.9%)
and for the clotting assay x"= 100 ± 2.6% of normal
activity (variation coefficient 2.6%) were obtained.
Day to day precision
For day to day precision, 137 ± 8.4 U/l (variation
coefficient 6.1%) were obtained with the amidolytic
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48 72
Fig. 3. Influence of storage at 4 °C on prekallikrein and factor
XII; D—Dkallikrein, ·—· factor XII (amidolytic
assay), ο—-ο factor XII (clotting method).
Interaction of factor XII with aprotinin
Aprotinin was added to the activation solution in con-
centrations ranging from 10"9 to 10"6 mol/1, and
simultaneously to kallikrein assays. Aprotinin is effec-
tive on kallikrein at concentrations of more than
10"8 mol/1. Even at a concentration of 10"6 mol/1, this
substance has a negligable effect on factor XII (fig. 5).
Activation of factor XII by Cl esterase:
Incubation of plasma with Cl esterase for 10 minutes
resulted in an activation of factor XII (fig. 6). In a
simultaneous assay with factor XH-deficient plasma,
only a negligable activity was detected which is likely
to be due to an unspecific splitting of the chromogenic
substrate by Cl esterase. A further experiment demon-
strated that the unspecific splitting of the chromogenic
substrate by Cl esterase amounted to less than 2% of
the splitting observed above. Cl q subcomponent in a
concentration ranging from 8.7 X 1012 to 175 X 1012








Fig. 5. Addition of aprotinin to the kailikrein (·) and to the
amidolytic factor XII assay (·).
0.100
0.050
50i "" 100 150
Factor XII activity (.U/U>
200
Fig. 4. Linearity of the amidolytic assay, obtained with human
normal plasma (standard conditions).
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Fig. 6. Activation of factor XII by addition of purified Cl
esterase (incubation time 10 minutes); · normal plasma,
* factor XII deficient plasma.
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Diagnostic evaluation of the chromogenic assay
and comparison with the clotting method
Using both methods factor XII was evaluated daily for
one week on 10 volunteers and on 10 patients with
deep vein thrombosis. Table 2 demonstrates that in the
case of the patients with deep vein thrombosis, factor
XII level was markedly lowered. Correlation of the mean
values obtained during one week with the amidolytic
assay on the one hand, and the clotting method on the
other hand resulted in a correlation coefficient of
r = 0.831 (p-value < 0.001) (fig. 7). Linear regression
analysis showed the equation: y = 0.759 χ + 23.
Discussion
Exposure of plasma to various negatively charged sur-
faces like kaolin, ellagic acid or dextran sulphate initiates
contact activation resulting in the activation of the
intrinsic coagulation, the kinin-forming, and the fibrinoly-
tic systems. Surface-binding of factor XII does not coil-
vert the inactive to the active form, but it makes factor
XII much more susceptible (100 to 500 fold) to proteoly-
tic activation by various proteases (11). These findings
confirm a previous report that the uptake of factor XII
onto kaolin is inhibited by plasma, resulting in an in-





Factor XII (chromogenic assay) lU / l ]
200
Fig. 7. Comparison of the amidolytic and the clotting assay. The
mean values obtained during one week in 20 patients are
compared; y = 0.759 χ + 23, r = 0.831 (p-value < 0.001).
Tab. 2. Factor XII levels of healthy donors and of patients with
deep vein thrombosis (DVT) (comparison of the mean
values).
Healthy donors (n = 10)












traces of kallikrein or other proteases like plasmin or
trypsiri, a sufficient activation of factor XII is observed
(1).
Attention must be drawn to the recent report by Col-
man (12), which attributes the coagulant activity of
factor XII to the factor XII a molecule. Coagulant
activity of factor XHf (fragment) is very poor, though
factor Xllf remains an activator of prekallikrein (12).
Furthermore, the findings ofColman (12) indicate that
factor XII f is identical with the pre-albumin activator
of prekallikrein, which was first reported by Kaplan &
Austen (13,14). These authors demonstrated that the
prealbumin activator is completely inhibited by
0.3 mol/1 sodium chloride. Consequently, factor XIIf
can be excluded by adding sodium chloride to the reac-
tion mixture. All this considered, prekallikreiri activation
in the assay is likely to be due to factor XII a activity.
It is known from the literature that kaolin cannot be
used as an activator in highly purified systems, as factor
XII is irreversibly bound to kaolin. However, in human
plasma, this effect is negligible (1). In our assay, human
normal plasma was taken as a prekallikrein source; con-
sequently the activator had to be removed from the
sample. Kaolin was added as an activator. An inactiva-
tion of factor Xft a by antithrombin HI, even in the
presence of heparin, seems unlikely, as antithrombin HI
does not have a high affinity for contact factors in the
presence of near normal concentrations of proteinase
inhibitors (19). Moreover, the factor Xlkdependent
generation of plasma kallikrein is not inhibited by addi-
tion of heparin, indicating that the activators of pre-
kallikrein are not counteracted by heparin (19).
Although comparison of the clotting assay with an
amidolytic assay reveals many problems, an attempt
was made to corfelate both methods. Comparison of the
mean values obtained from the observation period
resulted in an adequate correlation coefficient. Behaviour
of aprotinin as ascertained in this study conforms to
that ascertained in previous reports (15,16).
It is known from the literature (17) that the complement
system is activated by contact. However, to the best of
our knowledge an activation of factor XII by Cl esterase
has not been described. The findings of Kluft indicated
that Cl esterase is ineffective as an activator of pre-
kallikrein (2).
In order to gain further evidence of the interaction of
factor XII and the Cl component of the complement
system, the ability of Clq to activate factor XII was
explored. As our results revealed this subcomponent to
be ineffective, an esterolytic activation of factor XII can
b6 assumed. These findings could not be repeated with
plasma from a case of congenital factor XII deficiency;
they can therefore be attributed to an interaction of
Cl esterase and factor XII. This pathway demonstrates
the close connection of the complement arulxthe coagula-
tion systems.
J. Clin. Oiem, Clin..Biochem. / Vol. 19,1981 / No. 6
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The diagnostic relevance of the amidolytic assay was
evaluated in patients with deep vein thrombosis, as
already mentioned. Using the assay, the levels of
factor XII were found to be lowered during the observa-
tion period. Our results agree with the recent report of
Hedner who observed IgG antibodies directed against
factor XII in 11 young patients with severe thrombotic
disease (18). The author concluded that normal factor
XII levels are of importance for preventing the develop-
ment of deep venous thrombosis (18).
This report makes it desirable to assay factor XII with
a functional assay.
Taking these facts into account, determination of factor
XII can be regarded as one of the most sensitive para-
meters in thrombohemorrhagic diseases.
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